Biological markers of Pseudomonas aeruginosa epidemic high-risk clones

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5527-5535

  Mulet, Xavier ^a   Cabot, Gabriel ^a   Ocampo Sosa, Alain A ^b   Domínguez, M Angeles ^c   Zamorano, Laura ^a   Juan, Carlos ^a   Tubau, Fe ^c   Rodríguez, Cristina ^b   Moyà, Bartolomé ^a   Peña, Carmen ^c   Martínez Martínez, Luis ^b,d   Oliver, Antonio ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PYOCYANINE; PYOVERDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL PHENOMENA AND FUNCTIONS; BIOFILM; BLOODSTREAM INFECTION; CLINICAL ARTICLE; CLONE; CONTROLLED STUDY; EPIDEMIC; FITNESS; FLOW CYTOMETRY; GENOTYPE; HUMAN; IN VITRO STUDY; INFECTION CONTROL; MULTICENTER STUDY; MULTIDRUG RESISTANCE; MULTILOCUS SEQUENCE TYPING; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SPAIN; ST 111 CLONE; ST 175 CLONE; ST 235 CLONE; SWARMING MOTILITY; SWIMMING; TWITCHING MOTILITY;

ANTI-BACTERIAL AGENTS; BIOFILMS; BIOLOGICAL MARKERS; CLONE CELLS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EPIDEMICS; HUMANS; MICROBIAL SENSITIVITY TESTS; MULTILOCUS SEQUENCE TYPING; MUTATION; OLIGOPEPTIDES; PHYLOGENY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PYOCYANINE; RISK; SPAIN;

EID: 84885943133     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01481-13     Document Type: Article

References (51)

1. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitliks SD. 1998. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J. Intern. Med. 244:379-386.
2. Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, van Laethem Y, Jacobs F, Lebesque P, Malfroot A, Tulkens PM, van Bambeke F. 2007. Pseudomonas aeruginosa: resistance and therapeutics options in the turn of the new millennium. Clin. Microbiol. Infect. 13:560-578.
3. Peña C, Suarez C, Ocampo-Sosa A, Murillas J, Almirante B, Pomar V, Aguilar M, Granados A, Calbo E, Rodríguez-Baño J, Rodríguez F, Tubau F, Oliver A, Martínez-Martínez L, Spanish Network for Research in Infectious Diseases (REIPI). 2013. Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post hoc analysis of a prospective cohort. Clin. Infect. Dis. 57:208-216.
4. Lister PD, Wolter DJ, Hanson ND. 2009. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin. Microbiol. Rev. 22:582-610.
5. Deplano A, Denis O, Poirel L, Hocquet D, Nonhoff C, Byl B, Nordmann P, Vincent JL, Struelens MJ. 2005. Molecular characterization of an epidemic clone of panantibiotic-resistant Pseudomonas aeruginosa. J. Clin. Microbiol. 43:1198-1204.
6. Suarez C, Peña C, Arch O, Dominguez MA, Tubau F, Juan C, Gavaldá L, Sora M, Oliver A, Pujol M, Ariza J. 2011. A large sustained endemic outbreak of multiresistant Pseudomonas aeruginosa: a new epidemiological scenario for nosocomial acquisition. BMC Infect. Dis. 11:272. doi:10 .1186/1471-2334-11-272.
7. Pagani L, Colinon C, Migliavacca R, Labonia M, Docquier JD, Nucleo E, Spalla M, Li Bergoli M, Rossolini GM. 2005. Nosocomial outbreak caused by multidrug-resistant Pseudomonas aeruginosa producing IMP-13 metallo-beta- lactamase J. Clin. Microbiol. 43:3824-3828.
8. Peña C, Suarez C, Tubau F, Gutierrez O, Domínguez A, Oliver A, Pujol M, Gudiol F, Ariza J. 2007. Nosocomial spread of Pseudomonas aeruginosa producing the metallo-beta-lactamase VIM-2 in a Spanish hospital: clinical and epidemiological implications. Clin. Microbiol. Infect. 13: 1026-1029.
9. Van der Bij AK, Van Mansfeld R, Peirano G, Goessens WH, Severin JA, Pitout JD, Willems R, Van Westreenen M. 2011. First outbreak of VIM-2 metallo-β-lactamase-producing Pseudomonas aeruginosa in The Netherlands: microbiology, epidemiology and clinical outcomes. Int. J. Antimicrob. Agents 37:513-518.
10. Zavascki AP, Gaspareto PB, Martins AF, Gonçalves AL, Barth AL. 2005. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing SPM-1 metallo-beta-lactamase in a teaching hospital in southern Brazil. J. Antimicrob. Chemother. 56:1148-1151.
11. Woodford N, Turton JF, Livermore DM. 2011. Multiresistant Gramnegative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol. Rev. 35:736-755.
12. Cholley P, Thouverez M, Hocquet D, van der Mee-Marquet N, Talon D, Bertrand XJ. 2011. Most multidrug-resistant Pseudomonas aeruginosa isolates from hospitals in eastern France belong to a few clonal types. J. Clin. Microbiol. 49:2578-2583.
13. Empel J, Filczak K, Mrówka A, Hryniewicz W, Livermore DM, Gniadkowski M. 2007. Outbreak of Pseudomonas aeruginosa infections with PER-1 extended-spectrum beta-lactamase in Warsaw, Poland: further evidence for an international clonal complex. J. Clin. Microbiol. 45:2829-2834.
14. García-Castillo M, Del Campo R, Morosini MI, Riera E, Cabot G, Willems R, van Mansfeld R, Oliver A, Cantón R. 2011. Wide dispersion of ST175 clone despite high genetic diversity of carbapenemnonsusceptible Pseudomonas aeruginosa clinical strains in 16 Spanish hospitals. J. Clin. Microbiol. 49:2905-2910.
15. Maatallah M, Cheriaa J, Backhrouf A, Iversen A, Grundmann H, Do T, Lanotte P, Mastouri M, Elghmati MS, Rojo F, Mejdi S, Giske CG. 2011. Population structure of Pseudomonas aeruginosa from five Mediterranean countries: evidence for frequent recombination and epidemic occurrence of CC235. PLoS One 6:e25617. doi:10.1371/journal.pone.0025617.
16. Samuelsen O, Toleman MA, Sundsfjord A, Rydberg J, Leegaard TM, Walder M, Lia A, Ranheim TE, Rajendra Y, Hermansen NO, Walsh TR, Giske CG. 2010. Molecular epidemiology of metallo-beta-lactamaseproducing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. Antimicrob. Agents Chemother. 54:346-352.
17. Viedma E, Juan C, Acosta J, Zamorano L, Otero JR, Sanz F, Chaves F, Oliver A. 2009. Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. Antimicrob. Agents Chemother. 53:4930-4933.
18. Viedma E, Juan C, Villa J, Barrado L, Orellana MA, Sanz F, Otero JR, Oliver A, Chaves F. 2012. VIM-2 producing multidrug-resistant Pseudomonas aeruginosa ST175 clone, Spain. Emerg. Infect. Dis. 18:1235-1241.
19. Cabot G, Ocampo-Sosa AA, Domínguez MA, Gago JF, Juan C, Tubau F, Rodríguez C, Moyà B, Peña C, Martínez-Martínez L, Oliver A, Spanish Network for Research in Infectious Diseases (REIPI). 2012. Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones. Antimicrob. Agents Chemother. 56:6349-6357.
20. Martínez JL, Baquero F. 2002. Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance. Clin. Microbiol. Rev. 15:647-679.
21. Andersson DI, Hughes D. 2010. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat. Rev. Microbiol. 8:260-271.
22. Gooderham WJ, Hancock RE. 2009. Regulation of virulence and antibiotic resistance by two-component regulatory systems in Pseudomonas aeruginosa. FEMS Microbiol. Rev. 33:279-294.
23. Balasubramanian D, Schneper L, Kumari H, Mathee K. 2013. A dynamic and intricate regulatory network determines Pseudomonas aeruginosa virulence. Nucleic Acids Res. 41:1-20.
24. Baquero F. 2004. From pieces to patterns: evolutionary engineering in bacterial pathogens. Nat. Rev. Microbiol. 2:510-518.
25. Beceiro A, Tomás M, Bou G. 2013. Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world. Clin. Microbiol. Rev. 26:185-230.
26. Abdelraouf K, Kabbara S, Ledesma KR, Poole K, Tam VH. 2011. Effect of multidrug resistance-conferring mutations on the fitness and virulence of Pseudomonas aeruginosa. J. Antimicrob. Chemother. 66:1311-1317.
27. Moya B, Juan C, Albertí S, Pérez JL, Oliver A. 2008. Benefit of having multiple ampD genes for acquiring beta-lactam resistance without losing fitness and virulence in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 52:3694-3700.
28. Sánchez P, Linares JF, Ruiz-Díez B, Campanario E, Navas A, Baquero F, Martínez JL. 2002. Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants. J. Antimicrob. Chemother. 50:657-664.
29. Baquero F, Coque TM, de la Cruz F. 2011. Ecology and evolution as targets: the need for novel eco-evo drugs and strategies to fight antibiotic resistance. Antimicrob. Agents Chemother. 55:3649-3660.
30. Peña C, Suarez C, Gozalo M, Murillas J, Almirante B, Pomar V, Aguilar M, Granados A, Calbo E, Rodríguez-Baño J, Rodríguez F, Tubau F, Martínez-Martínez L, Oliver A, Spanish Network for Research in Infectious Diseases (REIPI). 2012. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob. Agents Chemother. 3:1265-1272.
31. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18: 268-281.
32. Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodríguez C, Moya B, Zamorano L, Suárez C, Peña C, Martínez-Martínez L, Oliver A, Spanish Network for Research in Infectious Diseases (REIPI). 2011. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrob. Agents Chemother. 55:1906-1911.
33. Juan C, Zamorano L, Mena A, Albertí S, Pérez JL, Oliver A. 2010. Metallo-beta-lactamase-producing Pseudomonas putida as a reservoir of multidrug resistance elements that can be transferred to successful Pseudomonas aeruginosa clones. J. Antimicrob. Chemother. 65:474-478.
34. Gilarranz R, Juan C, Castillo-Vera J, Chamizo FJ, Artiles F, Alamo I, Oliver A. 13 April 2013. First detection in Europe of the metallo-β- lactamase IMP-15 in clinical strains of Pseudomonas putida and Pseudomonas aeruginosa. Clin. Microbiol. Infect. doi:10.1111/1469-0691 .12248.
35. Vatcheva-Dobrevska R, Mulet X, Ivanov I, Zamorano L, Dobreva E, Velinov T, Kantardjiev T, Oliver A. 21 April 2013. Molecular epidemiology and multidrug resistance mechanisms of Pseudomonas aeruginosa isolates from Bulgarian hospitals. Microb. Drug Resist. doi:10.1093/cid/cit223.
36. Curran B, Jonas D, Grundmann H, Pitt T, Dowson CG. 2004. Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa. J. Clin. Microbiol. 42:5644-5649.
37. Rashid MH, Kornberg A. 2000. Inorganic polyphosphate is needed for swimming, swarming, and twitching motilities of Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U. S. A. 97:4885-4890.
38. Caiazza NC, Shanks RM, O'Toole GA. 2005. Rhamnolipids modulate swarming motility patterns of Pseudomonas aeruginosa. J. Bacteriol. 187: 7351-7361.
39. Merritt JH, Kadouri DE, O'Toole GA. 2005. Growing and analyzing static biofilms. Curr. Protoc. Microbiol. Chapter 1:Unit 1B.1. doi:10.1002/ 9780471729259.mc01b01s00.
40. Mena A, Smith EE, Burns JL, Speert DP, Moskowitz SM, Perez JL, Oliver A. 2008. Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J. Bacteriol. 190:7910-7917.
41. Oliver A, Cantón R, Campo P, Baquero F, Blázquez J. 2000. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288:1251-1254.
42. Koch B, Jensen LE, Nybroe O. 2001. A panel of Tn7-based vectors for insertion of the gfp marker gene or for delivery of clonedDNAinto Gramnegative bacteria at a neutral chromosomal site. J. Microbiol. Methods 45:187-195.
43. Eisen MB, Spellman PT, Brown PO, Botstein D. 1998. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U. S. A. 95:14863-14868.
44. Jarrell KF, McBride MJ. 2008. The surprisingly diverse ways that prokaryotes move. Nat. Rev. Microbiol. 6:466-476.
45. Feinbaum RL, Urbach JM, Liberati NT, Djonovic S, Adonizio A, Carvunis AR, Ausubel FM. 2012. Genome-wide identification of Pseudomonas aeruginosa virulence-related genes using a Caenorhabditis elegans infection model. PLoS Pathog. 8:e1002813. doi:10.1371/journal .ppat.1002813.
46. Lau GW, Hassett DJ, Ran H, Kong F. 2004. The role of pyocyanin in Pseudomonas aeruginosa infection. Trends Mol. Med. 10:599-606.
47. Visca P, Imperi F, Lamont IL. 2007. Pyoverdine siderophores: from biogenesis to biosignificance. Trends Microbiol. 15:22-30.
48. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322.
49. Hogardt M, Heesemann J. 2010. Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung. Int. J. Med. Microbiol. 300: 557-562.
50. Martínez-Solano L, Macia MD, Fajardo A, Oliver A, Martinez JL. 2008. Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin. Infect. Dis. 47:1526-1533.
51. Ciofu O, Mandsberg LF, Bjarnsholt T, Wassermann T, Høiby N. 2010. Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants. Microbiology 156:1108 -1119.